Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Death Receptor Pathway Activation and Increase of ROS Production by the Triple Epigenetic Inhibitor UVI5008

6 Oct 2011

Abstract excerpt

Deregulation of the epigenome is recognized as cause of cancer and epigenetic factors are receiving major attention as therapeutic targets; yet, the molecular mode of action of existing epi-drugs is largely elusive. Here, we report on the decryption of the mechanism of action of UVI5008, a novel epigenetic modifier, that inhibits histone deacetylases, sirtuins, and DNA methyltransferases. UVI5008 highly...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Epigenetics and DNA Methylation
Share to Histone Deacetylase Inhibitors Research
Share to Sirtuins and Resveratrol in Medicine

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 21980132
DOI: 10.1158/1535-7163.mct-11-0525

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Death Receptor Pathway Activation and Increase of ROS Production by the Triple Epigenetic Inhibitor UVI5008PMID 21980132Read ↗

Molecular Target and Action Mechanism of Anti-Cancer AgentsSemantic proximity Read ↗

The pharmacoepigenetic paradigm in cancer treatmentSemantic proximity Read ↗

Targeting apoptotic pathways for cancer therapySemantic proximity Read ↗

Understanding the Mechanisms by Which Epigenetic Modifiers Avert Therapy Resistance in CancerSemantic proximity Read ↗

A SIRT2-Selective Inhibitor Promotes c-Myc Oncoprotein Degradation and Exhibits Broad Anticancer ActivitySemantic proximity Read ↗

TACIMA-218: A Novel Pro-Oxidant Agent Exhibiting Selective Antitumoral Activity.Semantic proximity Read ↗

Therapeutic advancements in targeting BCL-2 family proteins by epigenetic regulators, natural, and synthetic agents in cancerSemantic proximity Read ↗

PARP inhibitor and PRMT5 inhibitor synergy is independent of BRCA1/2 and MTAP status in breast cancer cellsSemantic proximity Read ↗

Cediranib suppresses homology-directed DNA repair through down-regulation of BRCA1/2 and RAD51Semantic proximity Read ↗

RIP1–HAT1–SIRT Complex Identification and Targeting in Treatment and Prevention of CancerSemantic proximity Read ↗

p53 at the Crossroads between Different Types of HDAC Inhibitor-Mediated Cancer Cell DeathSemantic proximity Read ↗

Selective inhibition of SIRT2: A disputable therapeutic approach in cancer therapySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.